The aetiology and the pathogenesis of progressive systemic sclerosis (PSS) have not been well elucidated.' 2 PSS is characterised by vascular and microvascular abnormalities,l4 excessive fibroblastic activity,5 6 and collagen deposition in numerous organs. 17 A wide range of immunological abnormalities have been described in patients with this disorder.8 9 These findings include decreased numbers of circulating T lymphocytes, 105 decreased lymphocyte proliferation to mitogens,6 17 impaired antibody dependent, cell mediated cytotoxicity, '8 19 increased cell mediated immunity to skin extracts and collagen,20 and increased OKT4+/OKT8+ ratio with depressed numbers of OKT8+.15 21 considered to be a polyclonal B cell activator. 26 Thus EBV could be responsible for at least part of the sustained B cell activation in PSS. Several reports have shown a defective EBV specific suppressor T cell function in rheumatoid arthritis (RA), suggesting that EBV may have a role in the pathogenesis of RA.2$29 We and others have recently shown that several immunoregulatory defects exist in subgroups of RA patients.30 31 In this study we examined EBV specific T cell regulation in patients with PSS and in controls. Our results show that 50% of PSS patients have a strikingly defective suppressor T cell function of EBV induced B cell activation.
Patients and methods

PATI ENTS
Twenty patients with progressive systemic sclerosis and diffuse scleroderma (mean age 49-8±9-2 (SD) years; 18 women, two men) and 10 control subjects (mean age 56-6±16 3 years; eight women, two men) were studied. Table 1 .
In control subjects autologous T cells induced a significant suppression of IgM secretion by EBV activated B cells at 12 and 16 days of culture; the mean and individual results are shown in Fig. la .
In PSS patients autologous T cells also induced a significant suppression at 12 days of culture. At 16 days of culture, however, the difference of IgM secretion between B cell cultures and autologous B and T cell cocultures was not statistically significant ( Table 1) .
The suppression ratio in PSS patients was lower Fig. lc) .
Thus a suppression ratio lower or higher than 0.50 at 12 and 16 days of culture allowed the classification of PSS patients into two groups with definitely different T cell regulations. Group II was characterised by a defective T cell regulation. In contrast, group I had a T cell regulation similar to that of control subjects.
This in vitro study was repeated at six month intervals in seven patients (three patients in group I, four patients in group II). None of these patients was taking prednisone or slow acting therapeutic agents. Four of the seven patients were taking nonsteroidal anti-inflammatory drugs; the treatment had remained unchanged during this six month period. In each patient the results of these vitro assays were similar at six month intervals: all patients remained in the same subgroups (data not shown). Thus the classification of each individual PSS patient into one particular subgroup according to the in vitro abnormalities of EBV induced B cell activation seems to be a constant finding.
ROLE OF THE T:B CELL RATIO
It may be questioned whether different T:B cell ratios could influence these results. Parallel experiments were performed in 10 PSS patients in group I and five PSS patients in group II with three different T:B cell ratios: (a) 1:1; (b) 2:1; (c) 4:1 (B cells were at concentration of 0-5x106/ml and T cells were 0*5x106/ml (a), or 1-0x106/ml (b), or 2-0x106/ml (c)). In each patient the results of these in vitro assays were similar with the three T:B cell ratios used: all patients remained in the same subgroup (data not shown). Thus (Table 2) .
Discussion
The addition of EBV to lymphocytes in vitro induces the transformation of infected B lymphocytes; they become blasts, begin active DNA synthesis and rapid cell division, secrete immunoglobulin of all classes (but predominantly IgM), and finally, they produce lymphoblastoid cell lines. Thus EBV is considered to be a polyclonal B cell activator. 26 38 The activation by EBV of B lymphocytes does not require the participation of helper T cells,38 39 though T cells can negatively regulate this process.29 40 In normal subjects a T cell mediated suppression of immunoglobulin synthesis induced by EBV appears to be dependent on a cytotoxic or suppressor T cell population.40 Several In the present study we used a similar method to assess a possible immunoregulatory abnormality of EBV induced B cell activation in patients with PSS and diffuse scleroderma.
Our data clearly show that 50% of PSS patients have a strikingly defective T cell suppression of EBV induced B cell activation. We assessed T cell regulation by comparing IgM secretion into the supernatant of 16 day cultures of B cells alone and cocultures of autologous T and B cells. In all PSS patients studied as a group the suppression ratio was lower than that in control subjects at 12 and 16 days of culture. We have previously observed similar results in RA patients.
Analysis of individual results showed that using the value of the suppression ratio at 12 and 16 days of culture PSS patients could be classified into two subgroups: PSS group I was defined by a suppression ratio higher than 0-50 and PSS group II by a suppression ratio lower than 0-50. In PSS group I (10 patients) a significant T cell suppression was obvious, similar to that of controls. In contrast, PSS group II (10 patients) was characterised by a strikingly defective T cell suppression of EBV induced B cell activation as compared with control subjects. These results are similar to those obtained in our previous study of RA patients.30 Thus a suppression ratio higher or lower than 0-50 allows the classification of PSS patients into two groups characterised by a normal (group I) or a defective (group II) T cell suppression of EBV induced B cell activation.
This classification of PSS patients according to the in vitro abnormalities of EBV induced B cell activation seems to be a constant finding since similar results were obtained in PSS patients from both groups at six month intervals.
Furthermore, the T cell regulation defect could not be explained by a low T:B cell ratio since the use of higher (two-or It is yet to be determined whether the immunoregulatory defect we found is a primary phenomenon that can be implicated in the initiation or perpetuation of PSS in some cases, or whether it develops secondarily as a consequence of chronic disease.
The mechanisms, the cell subpopulations, the lymphokines, and other soluble factors possibly involved in the immunoregulatory defect are currently under study.
Other investigators have reported similar immunoregulatory defects in systemic lupus erythematosus.53 These findings suggest that EBV regulation defects are not unique to rheumatoid arthritis and can be found in subgroups of patients with different connective tissue diseases.
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